Education
About Us
Working with TipRanks
Follow Us
GlaxoSmithKline (GSK)
NYSE:GSK
Earnings Data
Report Date
Apr 29, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
1.17Last Year’s EPS
1.2Same Quarter Last Year
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
Overall the call was positive: GSK reported solid FY2025 financial results with strong cash generation, upgraded shareholder returns, robust specialty and HIV growth, multiple pipeline advances and R&D outputs (5 FDA approvals, 7 pivotal starts) and clear BD activity. Offsetting risks include vaccine softness in the U.S. and China inventory issues, product-specific launch execution challenges (BLENREP, ZEJULA), GenMed pricing/generic pressures, currency headwinds and one-off charges; however management provided explicit 2026 guidance (sales 3–5%, core op profit/EPS +7–9%) and articulated a plan to accelerate the pipeline and commercial execution which suggests the positives materially outweigh the negatives.Company Guidance
Strong Full-Year Financial Performance
Sales up 7% to more than GBP 32 billion; core operating profit up 11%; core EPS up 12%; operating margin improved by 110 basis points (reported margin 29.9% impacted by currency).
Robust Cash Generation and Capital Returns
Cash generated from operations GBP 8.9 billion (more than GBP 10 billion excluding Zantac); free cash flow GBP 4.0 billion (more than GBP 5.0 billion excluding Zantac); underlying free cash generation > GBP 8 billion before investments; shareholder distributions ~GBP 4 billion (dividend upgraded 2p to 66p declared; 2026 dividend guidance 70p, +6%); 93 million shares repurchased (avg price 1473) with remaining GBP 0.6 billion buyback to complete; net debt/EBITDA ~1.3x stable.
Specialty Medicines Driving Growth
Specialty medicines sales increased 17%; Respiratory Immunology & Inflammation +18% (Benlysta +22%; Nucala +15% and delivered $2 billion, marking 10th consecutive year of double-digit growth); Oncology: Jemperli +89%, Ojjaara +60%; BLENREP approved in 15 markets; Exdensur approved in U.S., U.K. and Japan. Company expects specialty sales to grow low double-digit in 2026.
HIV Franchise Momentum
HIV sales up 11% in FY2025 (U.S. +14%); Cabenuva grew 42% and now represents >75% U.S. uptake in the quarter; long-acting injectables accounted for >75% of growth and ~1/3 of U.S. sales; Aplitude (long-acting PrEP) grew 62%; guidance for HIV mid- to high-single-digit growth in 2026 and Q6M regimen selection planned mid-year with Phase II progression toward a 2028–2030 launch cadence.
Productive R&D and Pipeline Progress
Five FDA approvals in 2025 and seven new pivotal trial starts; several important programs advancing (Efimosfermin Phase III starts, Nebula planned, Bepirovirsen positive Phase III B‑WELL 1 & 2 readouts for chronic hepatitis B, KALM-2 last patient first visit for Camlipixant with mid-2026 Phase III data expected, DREAM trials and other pivotal starts planned); company plans ~10 pivotal starts in 2026 including >5 ADC pivotal starts and further oncology, MASH and HIV pivotal programs.
Active Business Development to Enhance Pipeline
Acquisition agreement to acquire Rapp Therapeutics (Ozureprubart, an anti-IgE for food allergy in Phase II); added 3 potentially best-in-class clinical-stage specialty assets via BD; continued focus on smart BD to accelerate portfolio value.
GSK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GSK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 04, 2026 | $52.92 | $56.78 | +7.29% |
Oct 29, 2025 | $42.97 | $45.17 | +5.10% |
Jul 30, 2025 | $36.64 | $37.91 | +3.45% |
Apr 30, 2025 | $37.48 | $38.32 | +2.26% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does GlaxoSmithKline (GSK) report earnings?
GlaxoSmithKline (GSK) is schdueled to report earning on Apr 29, 2026, Before Open (Confirmed).
What is GlaxoSmithKline (GSK) earnings time?
GlaxoSmithKline (GSK) earnings time is at Apr 29, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GSK EPS forecast?
GSK EPS forecast for the fiscal quarter 2026 (Q1) is 1.17.
